Several innovations have originated from the pool of unmet clinical needs identified by our Fellows and class students. Today, the innovation output of SSB has reached a tipping-point. Beyond 22 patents and 7 projects (initiated from the training programme) which attracted over $3.5 M in funding, SSB alumni have spin-off atleast 9 companies, 7 of which are in healthcare.

Within the first 2 years of the launch of the Fellowship Extension at SSB, 2 start-ups spun-off from SSB IP, namely Privi Medical and Advent Access Pte Ltd, both of which have successfully attracted private funding.

Advent Access

Advent Access is a medical technology startup in end stage renal disease management. Founded based on Stanford Biodesign principles and as a spin-off from A*STAR, Advent's mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. Advent Access' first product is the av-GuardianTM - an award winning device that aims to improve vascular access reliability, enable less-painful self-cannulation, and in the long run, preserves the health of an arteriovenous fistula. The av-GuardianTM forms a key component of Advent Access' dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely, and more affordably. Centered around the patient, the self-care platform seeks to disrupt how traditional in-center dialysis is delivered and increase the uptake of home hemodialysis. The company has raised S$4.2M of investments and research grants to date. For more information, please refer to

  • CEO & Founder - Mr. Peh Ruey Feng
  • Senior Medical Advisor - Prof Shervanthi Homer-Vanniasinkam
Board of Directors
  • Mr. Lu Yoh-Chie
  • Mr. Abel Ang
  • Mr. Peh Ruey Feng
Privi Medical

Privi is developing a product to help hemorrhoids sufferers manage their symptoms safely and effectively at home. Home managament of hemorrhoids presents a billion dollar global market opportunity. Privi was founded by fellows from the 4th Singapore Stanford Biodesign and is currently led by Mr. Prusothman Sina Raja, Dr.Benjamin Tee CK, Dr. Rena Dharmawan and Ms. Cecilia Wang. Privi has raised over S$1.1M from a combination of public and private funding.

For further information, please email Mr.Prusothman (  or Dr.Tee (

  • Mr. Prusothman Sina Raja
  • Dr. Benjamin Tee
  • Dr. Rena Dharmawan
  • Ms. Cecilia Wang